Abstract Background: Sacubitril/valsartan (SAC/VAL) is approved by the US Food and Drug
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …

Purpose Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular
mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily …

Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, reduces all-cause mortality
and the rate of heart failure hospitalizations in patients with heart failure with reduced …

Background: Sacubitril/valsartan is a first-in-class angiotensin-receptor neprilysin inhibitor
used to treat heart failure. The evidence for this novel medication is largely based on one …

Objective to evaluate the clinical efficacy and safety of sacubitril valsartan in the treatment of
heart failure (HF) with midrange ejection fraction after acute myocardial infarction (AMI) in …

Background Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor indicated for
the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; …

Aims The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696)
is recommended for the treatment of patients with heart failure in New York Heart …

Background Controversy has persisted over the clinical benefits of low‐dose
sacubitril/valsartan in patients with heart failure (HF). Hypothesis Low‐dose …

Background: The aim of this study was to observe the effect of Sacubitril/Valsartan on
cardiac function and remodeling in patients with heart failure with reduced ejection fraction …

Background: This study aims to systematically explore the efficacy of sacubitril valsartan
sodium tablet (SVST) for the treatment of chronic heart failure (CHF). Methods: Nine …